Amarin (AMRN) vs BridgeBio Oncology Therapeutics (BBOT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amarin (AMRN) has outperformed BridgeBio Oncology Therapeutics (BBOT) over the past year, losing 37.6% versus a loss of 71.8%. BridgeBio Oncology Therapeutics is the larger company by market cap ($263.4 million vs $251.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | BBOT |
|---|---|---|
| Share price | $11.89 | $3.29 |
| Market cap | $251.21M | $263.37M |
| 1-day change | -1.06% | -4.51% |
| YTD return | -13.90% | -72.52% |
| 1-year return | -37.62% | -71.83% |
| 5-year return | -88.35% | — |
| Forward P/E | 12.14 | — |
| EPS (TTM) | $-1.20 | $-0.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.90 | $14.87 |
| 52-week low | $11.83 | $3.27 |
| Distance from 52-week high | -43.10% | -77.91% |
| Analyst consensus | none | none |
| Avg. price target upside | +5.10% | +647.34% |
| Average volume | 66.16K | 468.83K |
| Shares outstanding | 21.12M | 80.17M |
| Employees | 80 | 88 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMRN has outperformed BBOT by 34.2 percentage points over the past year.
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About BridgeBio Oncology Therapeutics
BBOT stock →BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
AMRN vs BBOT FAQ
Which is bigger, Amarin or BridgeBio Oncology Therapeutics?
BridgeBio Oncology Therapeutics (BBOT) is larger, with a market capitalization of $263.37M compared with $251.21M for Amarin (AMRN).
Which stock has performed better over the past year, AMRN or BBOT?
AMRN returned -37.62% over the past 12 months, compared with -71.83% for BBOT (price return, excluding dividends). Past performance does not predict future results.
Are Amarin and BridgeBio Oncology Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.